Free Twice-Weekly Pharma Manufacturing Newsletter Stay current on Biopharma Packing & Security, Supply Chain Software & Systems, and Contract Manufacturing with a twice-weekly update sent straight to your Inbox. Join more than 30,000 pharma professionals who subscribe to FiercePharmaManufacturing for FREE!
A key element of a plan by KKR to invest in India's Gland Pharma is to boost its manufacturing capacity, and so significantly increase its earnings potential. Citing unnamed sources, The Economic Times said investment firm KKR is looking to take on a 40% share in the small but rapidly growing Gland Pharma in a deal valued at about $500 million. The deal would include the buyout of an existing investor, Evolvence India Life Science Fund, and a cash infusion of between $95 million and $110 million to pump up manufacturing. Story
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.
FiercePharmaManufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Click here to get your free twice weekly email briefing today!